알츠하이머병 뇌척수액 생물표지자 다기관 연구를 위한 예비연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박선아 | - |
dc.contributor.author | 김종헌 | - |
dc.contributor.author | 김형준 | - |
dc.contributor.author | 김태은 | - |
dc.contributor.author | 김윤정 | - |
dc.contributor.author | 이동현 | - |
dc.contributor.author | 박정호 | - |
dc.contributor.author | 채원석 | - |
dc.contributor.author | 임수재 | - |
dc.contributor.author | 서상원 | - |
dc.contributor.author | 나덕렬 | - |
dc.contributor.author | 최성혜 | - |
dc.date.accessioned | 2021-08-12T02:24:23Z | - |
dc.date.available | 2021-08-12T02:24:23Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1738-1495 | - |
dc.identifier.issn | 2384-0757 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14486 | - |
dc.description.abstract | Background: The usefulness of cerebrospinal fluid (CSF) concentrations of amyloid beta protein 1-42(Aβ42), phosphorylated tau (pTau) and total tau (tTau) have been increasing in Alzheimer’s disease (AD). However, the direct adoption of previously reported standard values is not appropriate due to interlaboratory variability. We started this study to set up an accessible system to measure CSF biomarkers in our country with high reproducibility and validity. Methods: Including CSFs from four different institutes the levels of Aβ42, pTau181 and tTau were measured in one lab. The intertest variability and difference in the levels of biomarkers depending on diseases were assessed. Through analysis of receiver operating characteristic cut points and binary logistic regression the cut-off values of Aβ42, pTau and tTau level were obtained, and their validity was evaluated. Results: The intertest consistency was high in measuring CSF biomarkers. The value of Aβ42 was markedly decreased in AD (n= 17) and other dementia (n= 9) compared to normal control (n= 12). The levels of pTau181 and tTau were high in AD, but not in other dementia and normal control. The threshold values of Aβ42, pTau181 and tTau were 290.3 pg/mL, 54.3 pg/mL, and 320.7 pg/mL in differentiating AD from normal control showing high sensitivity and specificity. Especially, the ratios of pTau181/Aβ42 (> 0.16) and tTau/Aβ42 (> 0.76) showed the prime validity. Conclusions:Our data of CSF Aβ42, pTau181, and tTau levels were highly reproducible. PTau181/Aβ42 and tTau/Aβ42 ratios were the greatly helpful in differentiating AD from normal control. | - |
dc.format.extent | 8 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한치매학회 | - |
dc.title | 알츠하이머병 뇌척수액 생물표지자 다기관 연구를 위한 예비연구 | - |
dc.title.alternative | Preliminary Study for a Multicenter Study of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.12779/dnd.2013.12.1.1 | - |
dc.identifier.bibliographicCitation | Dementia and Neurocognitive Disorders(대한치매학회지), v.12, no.1, pp 1 - 8 | - |
dc.citation.title | Dementia and Neurocognitive Disorders(대한치매학회지) | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.identifier.kciid | ART001758384 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Alzheimer’s disease | - |
dc.subject.keywordAuthor | Amyloid beta protein | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Enzyme-linked immunosorbent assay | - |
dc.subject.keywordAuthor | Cerebrospinal fluid | - |
dc.subject.keywordAuthor | Tau | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.